Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

Vincent D. de Jager; Wim Timens; Arnaud Bayle; Johan Botling; Luka Brcic; Reinhard Büttner; Maria Gabriela O. Fernandes; Libor Havel; Maximilian Hochmair; Paul Hofman; Annelies Janssens; Léon van Kempen; Izidor Kern; José Carlos Machado; Katja Mohorčič; Sanjay Popat; Aleš Ryška; Jürgen Wolf; Ed Schuuring; Anthonie J. van der Wekken

doi:10.1016/j.lanepe.2024.100839

Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

Vincent D. de Jager, Wim Timens, Arnaud Bayle, Johan Botling, Luka Brcic, Reinhard Büttner, Maria Gabriela O. Fernandes, Libor Havel, Maximilian Hochmair, Paul Hofman, Annelies Janssens, Léon van Kempen, Izidor Kern, José Carlos Machado, Katja Mohorčič, Sanjay Popat, Aleš Ryška, Jürgen Wolf, Ed Schuuring, Anthonie J. van der Wekken

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

8 Citations (Scopus)

Résumé

For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an explosive growth of newly introduced targeted therapies in oncology and this development is expected to continue in the future. Besides primary targetable aberrations, emerging diagnostic biomarkers also include relevant co-occurring mutations and resistance mechanisms involved in disease progression, that have impact on optimal treatment management. To accommodate testing of pending biomarkers, it is necessary to establish routine large-panel next-generation sequencing (NGS) for all patients with advanced stage NSCLC. For cost-effectiveness and accessibility, it is recommended to implement predictive molecular testing using large-panel NGS in a dedicated, centralized expert laboratory within a regional oncology network. The central molecular testing center should host a regional Molecular Tumor Board and function as a hub for interpretation of rare and complex testing results and clinical decision-making.

langue originale	Anglais
Numéro d'article	100839
journal	The Lancet Regional Health - Europe
Volume	38
Les DOIs	https://doi.org/10.1016/j.lanepe.2024.100839
état	Publié - 1 mars 2024
Modification externe	Oui

Accès au document

10.1016/j.lanepe.2024.100839

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

de Jager, V. D., Timens, W., Bayle, A., Botling, J., Brcic, L., Büttner, R., Fernandes, M. G. O., Havel, L., Hochmair, M., Hofman, P., Janssens, A., van Kempen, L., Kern, I., Machado, J. C., Mohorčič, K., Popat, S., Ryška, A., Wolf, J., Schuuring, E., & van der Wekken, A. J. (2024). Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer. The Lancet Regional Health - Europe, 38, Article 100839. https://doi.org/10.1016/j.lanepe.2024.100839

@article{39a85ac1148c4a0c883de86103e3329b,

title = "Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer",

abstract = "For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an explosive growth of newly introduced targeted therapies in oncology and this development is expected to continue in the future. Besides primary targetable aberrations, emerging diagnostic biomarkers also include relevant co-occurring mutations and resistance mechanisms involved in disease progression, that have impact on optimal treatment management. To accommodate testing of pending biomarkers, it is necessary to establish routine large-panel next-generation sequencing (NGS) for all patients with advanced stage NSCLC. For cost-effectiveness and accessibility, it is recommended to implement predictive molecular testing using large-panel NGS in a dedicated, centralized expert laboratory within a regional oncology network. The central molecular testing center should host a regional Molecular Tumor Board and function as a hub for interpretation of rare and complex testing results and clinical decision-making.",

keywords = "Next-generation sequencing, Non-small cell lung cancer, Predictive biomarker testing",

author = "{de Jager}, {Vincent D.} and Wim Timens and Arnaud Bayle and Johan Botling and Luka Brcic and Reinhard B{\"u}ttner and Fernandes, {Maria Gabriela O.} and Libor Havel and Maximilian Hochmair and Paul Hofman and Annelies Janssens and {van Kempen}, L{\'e}on and Izidor Kern and Machado, {Jos{\'e} Carlos} and Katja Mohor{\v c}i{\v c} and Sanjay Popat and Ale{\v s} Ry{\v s}ka and J{\"u}rgen Wolf and Ed Schuuring and {van der Wekken}, {Anthonie J.}",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors",

year = "2024",

month = mar,

day = "1",

doi = "10.1016/j.lanepe.2024.100839",

language = "English",

volume = "38",

journal = "The Lancet Regional Health - Europe",

issn = "2666-7762",

}

de Jager, VD, Timens, W, Bayle, A, Botling, J, Brcic, L, Büttner, R, Fernandes, MGO, Havel, L, Hochmair, M, Hofman, P, Janssens, A, van Kempen, L, Kern, I, Machado, JC, Mohorčič, K, Popat, S, Ryška, A, Wolf, J, Schuuring, E & van der Wekken, AJ 2024, 'Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer', The Lancet Regional Health - Europe, VOL. 38, 100839. https://doi.org/10.1016/j.lanepe.2024.100839

TY - JOUR

T1 - Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

AU - de Jager, Vincent D.

AU - Timens, Wim

AU - Bayle, Arnaud

AU - Botling, Johan

AU - Brcic, Luka

AU - Büttner, Reinhard

AU - Fernandes, Maria Gabriela O.

AU - Havel, Libor

AU - Hochmair, Maximilian

AU - Hofman, Paul

AU - Janssens, Annelies

AU - van Kempen, Léon

AU - Kern, Izidor

AU - Machado, José Carlos

AU - Mohorčič, Katja

AU - Popat, Sanjay

AU - Ryška, Aleš

AU - Wolf, Jürgen

AU - Schuuring, Ed

AU - van der Wekken, Anthonie J.

PY - 2024/3/1

Y1 - 2024/3/1

N2 - For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an explosive growth of newly introduced targeted therapies in oncology and this development is expected to continue in the future. Besides primary targetable aberrations, emerging diagnostic biomarkers also include relevant co-occurring mutations and resistance mechanisms involved in disease progression, that have impact on optimal treatment management. To accommodate testing of pending biomarkers, it is necessary to establish routine large-panel next-generation sequencing (NGS) for all patients with advanced stage NSCLC. For cost-effectiveness and accessibility, it is recommended to implement predictive molecular testing using large-panel NGS in a dedicated, centralized expert laboratory within a regional oncology network. The central molecular testing center should host a regional Molecular Tumor Board and function as a hub for interpretation of rare and complex testing results and clinical decision-making.

AB - For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an explosive growth of newly introduced targeted therapies in oncology and this development is expected to continue in the future. Besides primary targetable aberrations, emerging diagnostic biomarkers also include relevant co-occurring mutations and resistance mechanisms involved in disease progression, that have impact on optimal treatment management. To accommodate testing of pending biomarkers, it is necessary to establish routine large-panel next-generation sequencing (NGS) for all patients with advanced stage NSCLC. For cost-effectiveness and accessibility, it is recommended to implement predictive molecular testing using large-panel NGS in a dedicated, centralized expert laboratory within a regional oncology network. The central molecular testing center should host a regional Molecular Tumor Board and function as a hub for interpretation of rare and complex testing results and clinical decision-making.

KW - Next-generation sequencing

KW - Non-small cell lung cancer

KW - Predictive biomarker testing

UR - http://www.scopus.com/inward/record.url?scp=85186523281&partnerID=8YFLogxK

U2 - 10.1016/j.lanepe.2024.100839

DO - 10.1016/j.lanepe.2024.100839

M3 - Review article

AN - SCOPUS:85186523281

SN - 2666-7762

VL - 38

JO - The Lancet Regional Health - Europe

JF - The Lancet Regional Health - Europe

M1 - 100839

ER -